newsfilter
← Latest News
GlobeNewswire·

CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024

VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for